BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 31010330)

  • 1. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I; David M; Stemmer SM
    Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
    Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
    Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing skin toxicities related to panitumumab.
    Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
    J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xerosis and pruritus as major EGFRI-associated adverse events.
    Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
    Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
    Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
    Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA;
    Support Care Cancer; 2011 Aug; 19(8):1079-95. PubMed ID: 21630130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
    Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
    Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
    J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
    Yuan C; Wang B
    J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
    Braden RL; Anadkat MJ
    Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.